32 unknown. 32 Phase 2, 7 Phase 3, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 32 | Unknown 32 |
| Phase 3 | 7 | Unknown 7 |
| Phase 1 | 5 | Unknown 5 |
Follow Hepatitis C: new trials by email Literature Review of Hepatitis C trials Research Report on Hepatitis C
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder Glecaprevir/pibrentasvir, Placebo - PTSD | Phase 2 / Phase 3 | Unknown | White River Junction Veterans Affairs Medical Center | 92 | 2023-12-18 | 2025-04-24 |
| Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA). Prolonged-Release Pirfenidone - Liver Cirrhosis, Hepatitis C, Chronic | Phase 2 | Unknown | University of Guadalajara | 60 | 2019-08-01 | 2023-07-06 |
| Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients Seraprevir, Sofosbuvir - Hepatitis C Virus Infection | Phase 2 | Unknown | Ginkgopharma CO., LTD | 36 | 2019-04-03 | 2019-10-01 |
| SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C SH229 tablets, Daclatasvir dihydrochloride - Hepatitis C, Chronic | Phase 2 / Phase 3 | Unknown | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 440 | 2019-03-29 | 2019-08-28 |
| Outcomes Mandate National Integration With Cannabis as Medicine Cannabis, Medical, RYAH-Medtech Inhaler - Chronic Pain, Chronic Pain Syndrome | Phase 2 | Unknown | OMNI Medical Services, LLC | 200000 | 2018-12-01 | 2022-06-02 |
| Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma Ledipasvir and sofosbuvir - Indolent Lymphoma | Phase 2 | Unknown | National Taiwan University Hospital | 21 | 2017-09-01 | 2017-08-25 |
| Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis Patients Ombitasvir, Paritaprevir and Ritonavir - Chronic Hepatitis c | Phase 2 | Unknown | Ain Shams University | 40 | 2016-11-09 | 2018-01-18 |
| Strategic Transformation of the Market of HCV Treatments sofosbuvir + ravidasvir - Hepatitis C | Phase 2 / Phase 3 | Unknown | Drugs for Neglected Diseases | 603 | 2016-09-01 | 2021-01-20 |
| Mesenchymal Stem Cells Transplantation for Liver Cirrhosis Due to HCV Hepatitis Mesenchymal Stem Cells - Liver Cirrhosis | Phase 1 / Phase 2 | Unknown | Saglik Bilimleri Universitesi Gulhane Tip Fakultesi | 5 | 2016-01-01 | 2016-06-07 |
| A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4 ravidasvir hydrochloride, sofosbuvir, ribavirin - Chronic Hepatitis C | Phase 2 / Phase 3 | Unknown | Pharco Pharmaceuticals | 300 | 2015-01-01 | 2016-04-07 |
| A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets), Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection, Rebetol® (ribavirin), 1000/1200mg by mouth daily - Chronic Hepatitis C | Phase 2 | Unknown | St Vincent's Hospital Melbourne | 30 | 2013-09-01 | 2013-09-24 |
| Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection Miravirsen, Telaprevir, Ribavirin - Hepatitis C, Chronic | Phase 2 | Unknown | Santaris Pharma A/S | 20 | 2013-06-01 | 2014-11-18 |
| Clinical Investigation of Erlotinib as an HCV Entry Inhibitor 1- Erlotinib, placebo - Chronic Hepatitis C Infection, HCV Genotype 1b | Phase 1 / Phase 2 | Unknown | University Hospital, Strasbourg, France | 12 | 2013-05-01 | 2014-06-17 |
| Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Miravirsen sodium - Hepatitis C | Phase 2 | Unknown | Santaris Pharma A/S | 10 | 2012-11-01 | 2014-01-06 |
| Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance metformin, pegylated-IFN, ribavirin - Chronic Hepatitis c, Insulin Resistance | Phase 2 / Phase 3 | Unknown | Kaohsiung Veterans General Hospital. | 120 | 2012-08-01 | 2012-08-14 |
| Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant Rifaximin, Placebo - Hepatitis C | Phase 2 | Unknown | Columbia University | 59 | 2012-03-01 | 2016-04-22 |
| BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C BIP 48 (Peginterferon alfa 2b 48kDA), Peginterferon alfa 2a 40kDA - Chronic Hepatitis C | Phase 2 / Phase 3 | Unknown | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 740 | 2012-01-01 | 2012-06-20 |
| Effects of Vitamin D on Inflammation in Liver Disease Vitamin D, Placebo - Hepatitis C Infection, Vitamin D Deficiency | Phase 2 | Unknown | Veterans Medical Research Foundation | 24 | 2011-11-01 | 2012-12-21 |
| Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects anti-CD3 monoclonal antibody, Sodium Chloride placebo - Chronic Hepatitis C | Phase 2 | Unknown | Inspira Medical AB | 36 | 2011-11-01 | 2011-10-25 |
| CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects ChronVac-C + SOC, SOC - Chronic Hepatitis C | Phase 2 | Unknown | ChronTech Pharma AB | 32 | 2011-04-01 | 2011-10-12 |
Showing 20 of 32. Sign in to see all of them.
Hepatitis C, Chronic (17) · Liver Cirrhosis (3) · Liver Diseases (3) · Virus Diseases (3) · Acquired Immunodeficiency Syndrome (2) · Depression (2) · Hepatitis (2) · Hepatitis, Chronic (2) · Stress Disorders, Post-Traumatic (2) · Amyotrophic Lateral Sclerosis (1) · Anemia, Sickle Cell (1) · Anxiety Disorders (1) · Autistic Disorder (1) · Bipolar Disorder (1)
Blood-Borne Infections (32) · Communicable Diseases (32) · Digestive System Diseases (32) · Flaviviridae Infections (32) · Hepatitis, Viral, Human (32) · RNA Virus Infections (32) · Infections (31) · Hepatitis (30) · Liver Diseases (29) · Virus Diseases (29) · Pathologic Processes (23) · Pathological Conditions, Signs and Symptoms (23) · Chronic Disease (20) · Disease Attributes (20) · Hepatitis, Chronic (17)
Ribavirin (8) · peginterferon alfa-2a (4) · Sofosbuvir (3) · Interleukin-7 (2) · Rifaximin (2) · miravirsen (2) · peginterferon alfa-2b (2) · ravidasvir (2) · Fatty Acids, Omega-3 (1) · Hydroxychloroquine (1) · Hymecromone (1) · Medical Marijuana (1) · Metformin (1) · N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (1) · Pharmaceutical Preparations (1)
Cytheris SA (2) · Santaris Pharma A/S (2) · Ain Shams University (1) · BioGeneric Pharma (1) · BioWest Therapeutics Inc (1) · Bnai Zion Medical Center (1) · ChronTech Pharma AB (1) · Columbia University (1) · Drugs for Neglected Diseases (1) · Ginkgopharma CO., LTD (1) · Hepasome Pharmaceuticals (1) · Inspira Medical AB (1) · Kaohsiung Veterans General Hospital. (1) · MTmedical Institute of Health (1) · Nanjing Sanhome Pharmaceutical, Co., Ltd. (1)
United States (9) · Egypt (3) · France (3) · Puerto Rico (3) · Australia (2) · Austria (2) · Canada (2) · China (2) · Italy (2) · Poland (2) · Spain (2) · Taiwan (2) · Brazil (1) · Germany (1) · India (1)
Alexander Thompson, MBBS (1) · Amanda Quevedo, Sub Coord (1) · Anastacio M Hoyumpa, Prof. M.D. (1) · Anders G Vahlne, Professor (1) · Bradley V Watts, MD, MPH (1) · Charles T Leach, Prof. M.D. (1) · Daiana V. Gomes, AssitSocial (1) · Dharmesh Kapoor, MD (1) · Dr Catherine Mutter, MD (1) · Dr Samira Fafi-Kremer, Pharma D, PhD (1) · Dr. Ryan O Lakin, MD JD (1) · Dubravko Pavlin, PhD (1)
PMID 24876849, PMID 25042797, PMID 25043197, PMID 26006200, PMID 28935432, PMID 33865507, PMID 34307188, PMID 35080256, PMID 37055910, PMID 37856013, PMID 41044745
2009 (1)